Skip to main content
logo
Acrivon Therapeutics, Inc. (ACRV)
NASDAQ: ACRV · Real-Time Price · USD
1.915
+0.065 (3.51%)
Sep 21, 2026, 11:49 AM EDT - Market open

Acrivon Therapeutics Ratios and Metrics

Millions USD. Fiscal year is Jan - Dec.

Total Valuation

Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Market Capitalization
8276187109241-
Market Cap Growth
67.24%-59.43%71.66%-54.61%--
Enterprise Value
-6-504-28291-
Last Close Price
1.852.416.024.9211.52-

Price Ratios

Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
PB Ratio
0.910.681.060.901.41-
P/TBV Ratio
0.910.681.060.901.41-

Financial Efficiency

Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Debt / Equity Ratio
0.020.020.020.040.030.06
Net Debt / Equity Ratio
-1.01-1.03-0.99-1.01-0.72-0.95
Net Debt / EBITDA Ratio
1.141.401.991.853.805.82
Net Debt / FCF Ratio
1.371.772.572.803.806.61
Quick Ratio
7.867.5710.439.5819.6134.18
Current Ratio
7.997.6910.559.7520.2734.46
Return on Equity (ROE)
-64.63%-53.86%-54.07%-41.41%-23.16%-32.40%
Return on Assets (ROA)
-38.02%-32.22%-33.30%-26.25%-14.18%-18.60%
Return on Capital Employed (ROCE)
-89.40%-73.70%-49.70%-53.70%-18.70%-15.60%

Yields

Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Earnings Yield
-93.63%-102.44%-42.98%-55.30%-12.95%-
FCF Yield
-80.90%-85.91%-36.51%-40.23%-13.42%-
Buyback Yield / Dilution
-2.97%-13.96%-53.05%-435.63%-136.43%-21.70%
SEC Filings: 10-K · 10-Q